Performing an Effective, Robust and Compliant Sterility Failure Investigation: How to Avoid Common Mistakes

This training program will highlight mistakes often made when corrective and preventative actions are not clearly identified and applied during a manufactured product sterility test failure investigation because an ineffective investigational procedure and tool was used to conduct a sterility test failure investigation. The webinar will also illustrate how avoiding such common mistakes will ensure that these types of products meet the sterility requirements USP <71> and other regulatory guidelines applicable to finished products, bulk drug substance, raw materials or excipients.

Recorded Version Only

(PPT + Recorded Streaming Link)

$299.00
1x Person - Unlimited viewing for 6 Months (For multiple locations contact Customer Care)
rec Recorded Link and Ref. material will be available in My Account Section
Last Recorded Date: Sep-2019

CD or USB Drive Only

(PPT + Recorded Training File)

$399.00
One CD/USB is for usage in one location only.
(For multiple locations contact Customer Care)
CD/USB and Ref. material will be shipped within 15 business days
Customer Care

Fax: +1-650-362-2367

Email: customercare@fdatrainingalert.com

Follow us:
Why Should You Attend:

This training session will provide an understanding of the regulations guiding the sterility testing program and the process of conducting an effective, robust and compliant sterility test investigation for various types of sterile products. Attendees will gain an understanding of:

  • The step by step investigational tool to apply when conducting sterility test failure investigation.
  • How to delineate between a probable and an affirmative root cause using the recovered contaminant based on the investigational findings.
  • Possible corrective and preventative actions and how to apply the results of the investigation (investigational findings) to other manufactured batches of products within the same cleanroom.
  • Disposition of the manufactured batch of product with a failed sterility test result, regulatory guidelines associated with a retest of the affected batch and handling a sterility failure associated with a commercially distributed product under stability testing program.

The content of a sterility test investigation form to provide robustness to an investigational process will be shared with the attendees as a tool that may be used when designing a sterility failure investigation program.

Learning Objectives:
  • Discuss the regulations guiding manufactured product sterility testing such as USP <71> Sterility Testing and how to ensure adherence to program testing requirements.
  • Step by step process in conducting sterility test failure investigation and what to look for during the entire investigation process.
  • Discuss the role of contaminant as a key tool during investigational process such as microbial identification of contaminant and if it is important or not important - why or why not?
  • Performing a product retest during a sterility failure investigation and how to apply corrective and preventative action based on the findings of a sterility failure investigation.
  • How to disposition impacted products based on investigational findings while avoiding common mistakes during product disposition.
  • Impact of sterility failure investigation for commercially distributed products under a stability testing program.
Areas Covered in the Webinar:

Module#1 (Requirements of a Sterility Testing Program and Initial Consideration during a Sterility Failure Investigation)

  • Regulations Guiding Manufactured Product Sterility Testing
    • USP <71> Sterility Testing
  • Ensuring Adherence to Program Testing Requirements
    • Aseptic Processing
    • Contamination Control
    • Appropriateness of Testing Facility
    • Appropriateness of Testing Personnel
    • Training/Competencies
  • Initial Considerations During a Sterility Test failure Investigation
    • Affected Departments and Roles
      • Role of Quality Control
      • Role of Quality Assurance
      • Role of Manufacturing or Operations
      • Role of Facility or Engineering
      • Role of Regulatory Affairs
    • The Sterility Failure Notification Process
      • Initial Documentation Process during an Investigation
    • What Happens to the Affected Product Batch
      • Handling Affected Batch (or Batches) of the Product

Module#2 (Step by Step Process of Conducting an Effective, Robust and Compliant Sterility Test Failure Investigation)

  • Step by Step Process In Conducting Sterility Test Failure Investigation
    • What to Look for During the Investigational Process
      • Role of Personnel Handling and Cleanroom Behavior
      • Role of Testing Materials, Equipment and Media
      • Role of Environmental Monitoring or Testing
      • Role of Disinfection and Practices
      • Role of Testing Facility
      • Role of Laboratory Environment (Incubation)
      • Role of Training
      • Role of Environmental Controls
      • Role of Classified Testing Locations
      • Role of Room and Materials Qualification (Various)
      • Role or Microbial Identification
      • Role of Previous Product Sterility Test Failure Trends and Reports
      • Role of Previous Trends and Reports
      • Other Important Aspects
    • Role of Contaminant as a Key Tool During Investigational Process
      • Microbial Identification of Contaminant
        • Important or Not Important? Why or Why Not
      • Using a Process Map of Contaminant as a Tool for Root Cause Analysis
        • How to Utilize Identified Contaminant to Perform a Sterility Test Failure Investigation
        • Root Cause Analysis Process
        • Most Probable Root Cause versus Final Root Cause

Module#3 (Effective a Robust Corrective Actions, Preventative Actions, Sample of Investigation Forms, Product Disposition Process and Avoiding Common Mistakes)

  • Sample of Sterility Failure Investigation Forms
    • Important Sections
    • Effective Investigational Tools
  • Performing a Product Retest During a Sterility Failure Investigation
    • Regulatory Requirements Applicable to Product Retest
      • When to Perform a Product Retest
      • When not to Perform a Product Retest
  • Applying Corrective and Preventative Action Based on Findings of a Sterility Failure Investigation
    • Appropriateness of the Corrective Action
    • Appropriateness of the Preventative Action
    • Examples of Corrective And Preventative Actions
  • Disposition of the Products Based on Investigational Findings
    • How to Determine a False Positive Result
    • Dispositioning Products After a Sterility Failure Investigation
    • Avoiding Common Mistakes During Product Disposition
      • Role of QA
      • What Happens After Product Disposition
  • Impact of Sterility Failure for Commercially Distributed Products under a Stability Testing Program
    • Commercial Impact-Product Out in the Market
    • What Happens Next if a True Contamination or Failure is Discovered
    • Role of Regulatory Affairs
    • Agency Notification Process
  • Avoiding Common Mistakes During
    • When not to Ignore - An Early Warning Sign of a Systemic Issue
    • When not to Ignore - An Effective Implementation of Adequate Corrective Action and Preventative Action
Who Will Benefit:

This webinar will provide a great resource to personnel involved within the following departments in the pharmaceutical, biotechnology, diagnostics, drugs, cell therapy, biologics, raw material, excipients, chemicals and API suppliers, and medical device industries:

  • Quality Control
  • Sterility Assurance
  • Manufacturing/Production
  • Senior Management
  • Raw Materials Tester
  • Supplier Quality
  • Regulatory Affairs
  • Quality Assurance
  • Compliance
  • Design Engineers
  • Facility, Maintenance and Engineering
  • Contract Manufacturing Organizations (CMO)
  • Active Pharmaceutical Ingredients Suppliers
  • Chemical Suppliers
  • Excipient Suppliers
Instructor Profile:
Charity Ogunsanya Charity Ogunsanya

Director of Quality Control, Pharmabiodevice Consulting LLC

Charity Ogunsanya has over 26 years of extensive experience within the Pharmaceutical, Biotechnology, Biologics, Cell-Therapy, Diagnostics, Research and Development, Radio-pharmaceutical, Contract Manufacturing Organization (CMO) and Medical Device companies.

Throughout her corporate career within these diverse industries, she held various high visibility and business critical roles within the Quality and Compliance division in major Fortune 100 companies both as a Subject Matter Expert (SME), Site Manager, Multi-site Manager and Director Levels receptively. She has been a sought after expert and have been consistently hired after several competitive efforts by major fortune 100 companies to assume key roles specifically related to remediation and difficult Quality and Compliance related deficiencies associated with FDA’s Consent Decree, FDA’s Warning Letters and difficult regulatory bodies inspectional findings which is always achieved with a successful outcome. She has also been a sought after expert by various companies requesting her expertise as a known industry expert to specifically assume roles in order to perform a total overhaul, restructure, compliance remediation, re-organization, start-up processes related to Quality Systems improvements and/or enhancements. In all cases, her remediation work resulted in several successful National and International regulatory bodies’ inspections, re-inspection and new product approvals.

Her technical expertise are not limited to the interpretation, administration and set up of Quality Assurance, Quality/Compliance, Quality Engineering, Aseptic Processing, Contamination Control, Quality Control, Microbiology, Sterility Assurance, Stability, Vaccine Development, New Product Design, Product Release Testing and Medical Device Sterilization (Ethylene Oxide (EtO), Gamma, Radiation, VHP sterilization) systems and operations for compliance to various regulations.

Ms. Ogunsanya is vast in the requirements and regulations guiding new and existing products from planning through design, proof of concept, research and development, technology transfer, pre-clinical, clinical, commercial manufacturing, supply chain, regulatory filings, pre-approval inspections, licensure, government affairs, commercialization and post-approval inspections. Her expertise has been sought after by several Fortune 100 Pharmaceutical, Biotechnology, Biologics and Medical Device companies as a Quality and Compliance SME during critical national and international regulatory bodies’ routine and new product approval inspections.

She is the CEO of Pharmabiodevice Consulting LLC (www.pharmabiodeviceconsultant.com) targeted towards Quality and Compliance related remediation, enhancements and consultant services for various companies within the industry. She is a well sought after high level consultant for several international professional expert networks such as Gerson Lehrman Group, Zintro Expert Network and Intota Expert Network. She is a member of the Parenteral Drug Association (PDA), American Society of Microbiologists (ASM), and other Scientific Forums and Industry Expert Network.

Topic Background:

Performing an effective, robust, complete and compliant sterility test result failure investigation is an effective tool that helps to prevent future loss of product, regulatory filed complaint and product recalls. Further contamination of subsequently manufactured batches of finished products, raw materials, bulk drug substance or excipient may be prevented if the source of the contaminant is clearly identified at the onset of the initial sterility test failure investigation using an effective and compliant investigational process or tool.

Refund Policy

Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. FDATrainingAlert would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.

Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.

If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.

We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email customercare@fdatrainingalert.com call +1-888-771-6965 (Toll Free).

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

You Recently Viewed